Nuformix receives new NXP001 development milestone payments in updated Oxilio agreement

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd.

Under the revised agreement with, Oxilio will acquire ownership of Nuformix’s NXP001 patent estate, with Nuformix receiving the additional milestone payments referred to above, whilst retaining further development milestones and royalties capped at £2 million per year.

Read the full article

Click to view all articles for the EPIC: NFX
Or click to view the full company profile:
Nuformix plc

Nuformix excited as it moves focus to NXP002 and NXP004 programmes

19th September 2023

Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001 exclusive licensing agreement. In this interview Dr Dan Gooding outlines what the revised agreement covers, explains what it means for Nuformix and how

Nuformix hosting online Q&A session on 13 June 2023

2nd June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT

Nuformix appoints Kreston Reeves as auditor

25th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves will be

Nuformix plc has a complete pre-clinical story for potential licensing partners (VIDEO)

22nd May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting reference date from

Nuformix continuing to generate value-adding data for its lead programme

22nd May 2023

Nuformix delighted with NXP002 study results

18th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled

Nuformix to raise £70,000 through subscription, to progress NXP002

17th April 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced a subscription to raise gross proceeds of £70,000 through a subscription for 35,000,000 new ordinary shares of 0.1

Nuformix “tranilast at the heart of NXP002” in treating fibrosis (LON:NXF)

12th April 2023

Nuformix’s Dan Gooding discusses what the NXP002 programme is & its purpose, key findings from the results, and what’s next for the company and the programme in this exclusive interview with DirectorsTalk.

Nuformix Dan Gooding says NXP002 meets best case scenario objectives (VIDEO)

29th March 2023

Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP002 study results. Dan is delighted to remind us of what the NXP002 programme is and its purpose, take us through the key

Nuformix updates on the NXP002 programme for treatment of IPF

27th March 2023

Nuformix further evaluating NXP002 combination therapies now underway

15th February 2023

Nuformix updates on NXP004

20th December 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP004 programme, focused on the development of novel, proprietary, cocrystal forms of olaparib,

Nuformix excited by prospects for the remainder of the year

13th December 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 30 September 2022. Operational highlights (including post-period end) · Initial pre-clinical inhalation studies undertaken

Nuformix: Unlocking therapeutic potential in Fibrosis and Oncology

10th November 2022

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Nuformix to host online presentation and Q&A session

4th November 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9

Nuformix lead programme introduced to major respiratory players (VIDEO)

23rd September 2022

Nuformix introduces lead programme to major respiratory players